Objective: To investigate the relationship between surgeon’s experience, tumor characteristics, absent detrusor muscle (DM) tissue in resected specimens, and residual tumor after an initial transurethral resection. Patients and Methods: We conducted an analysis of 216 patients from two centers over a 3-year period. Patients with primary bladder tumors that were judged to have been completely resected were recruited. The data included tumor characteristics, surgeon category, and DM status. Logistic regression multivariate analyses were conducted. Results: Large tumors, lateral/dome/anterior wall tumors, and surgery performed by junior surgeons were independently associated with absent DM. Large tumors, dome/anterior wall tumors, T1 and absent DM were independently associated with residual disease. The absence and presence of the DM were associated with residual tumor rates of 51.8 and 20.9%, respectively (OR 15.537). Resection by senior surgeons was associated with the presence of DM and clean resection (OR 0.274 and 0.141, respectively). Conclusions: Absent DM and residual tumor were more likely to occur in cases involving large tumors that were located in the lateral/dome/anterior wall, especially when the surgery was performed by a junior surgeon. Absent DM appears to be a surrogate marker for residual disease.

Keywords:
Tumor characteristics, Surgeon category, Detrusor muscle, Transurethral resection, Bladder tumor, Residual tumor
1.
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303–314.
2.
Herr HW, Donat SM: Quality control in transurethral resection of bladder tumours. BJU Int 2008;102:1242–1246.
3.
Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B: The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003;43:241–245.
4.
Mariappan P, Zachou A, Grigor KM: Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010;57:843–849.
5.
Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB: An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003;169:110–115.
6.
Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, Dalbagni G: Treatment paradigm shift may improve survival of patients with high-risk superficial bladder cancer. J Urol 2007;177:1283–1286.
7.
Wein AJ: Campbell-Walsh Urology, ed 9. Philadelphia, Elsevier, Saunders, 2007.
8.
Brausi M, Collette L, Kurth K, der Meijden AP v, Oosterlinck W, Witjes JA, Newling D, Bouffioux C, Sylvester RJ: Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41:523–531.
9.
Jakse G, Algaba F, Malmstrom PU, Oosterlinck W: A second-look TUR in T1 transitional cell carcinoma: why. Eur Urol 2004;45:539–546.
10.
Kurth K, Schroeder FH, Debruyne F, Senge T, Pavone-Macaluso M, de Pauw M, ten KF, Sylvester R: Long-term follow-up in superficial transitional cell carcinoma of the bladder: prognostic factors for time to first recurrence, recurrence rate, and survival. Final results of a randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone. EORTC Genitourinary Tract Cancer Cooperative Group. Prog Clin Biol Res 1989;303:481–490.
11.
Herr HW, Donat SM: A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006;97:1194–1198.
12.
Balbay MD, Cimentepe E, Unsal A, Bayrak O, Koc A, Akbulut Z: The actual incidence of bladder perforation following transurethral bladder surgery. J Urol 2005;174:2260–2263.
13.
Herr HW, Donat SM, Dalbagni G: Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy. J Urol 2007;177:75–79.
14.
Zurkirchen MA, Sulser T, Gaspert A, Hauri D: Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol Int 2004;72:99–102.
15.
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997–1008.
16.
Dalbagni G, Herr HW, Reuter VE: Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 2002;60:822–825.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.